Cure8 news brief
Fibrostenosing (stricturing) Crohn’s disease is a major cause of complications and surgeries. Early-phase clinical results about a therapy targeting fibrotic strictures could matter to people facing strictures or recurrent obstruction.
This report is from the company presenting Phase IIa open-label extension data—informative for development but not definitive clinical evidence.
Patients with fibrostenosing Crohn’s disease; clinicians managing strictures; IBD researchers; investors tracking IBD therapeutics.
AgomAb presented open-label extension results from its Phase IIa STENOVA study testing a therapy for fibrostenosing (fibrosing) Crohn’s disease. The webcast transcript includes company executives and clinical investigators describing the extension data and next steps.
Discussion centers on treating fibrostenotic complications of Crohn’s disease and clinical development plans. The presentation is a company-hosted investor/KOL event; reporting focuses on the company’s interpretation of interim clinical data rather than an independent peer-reviewed publication.
The results discussed appear to relate to reducing or managing strictures and need for interventions in fibrostenosing disease, and to plans for further development.
Source is a company-hosted investor and KOL webcast (Seeking Alpha transcript). Open-label extension data are preliminary and uncontrolled; interpret cautiously. The transcript reflects company and investigator comments rather than a peer-reviewed article. Additional controlled trials will be needed to confirm benefit.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...
This report describes open‑label extension data for ontunisertib, an investigational oral drug being tested specifically for fibrostenosing Crohn’s disease.
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
